Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
25 November 2020 Photo Anja Aucamp
Prof Colin Chasi outside Centenary Complex (Anja Aucamp)
Prof Colin Chasi is the Director of the Unit for Institutional Change and Social Justice at the UFS.
The 2020 programme around the 16 Days of Activism against Gender-Based Violence will be novel in that it will be run online. “For each person to register and log into the various programmes is a small step. But each such step makes a big difference by saying that the lives of survivors matter and by underscoring that gender-based violence will not be tolerated at the UFS,” says Prof Colin Chasi, Director of the Unit for Institutional Change and Social Justice (UICSJ) at the UFS.

Women and girl children have experienced increased violence in the time of the COVID-19 lockdown, states the UN Secretary General's report, Shared Responsibility, Global Solidarity: Responding to the socio-economic impacts of COVID-19. In South Africa, there have been reports of a scourge of rape in the post-school education and training sector. At the UFS, these developments have challenged the Gender Equity and Anti-Discrimination Office (GEADO) to come up with innovative online interventions.

In 2019, the University of the Free State (UFS) established the Unit for Institutional Change and Social Justice (formerly known as the Institute for Reconciliation and Social Justice, founded in 2009). The GEADO was launched on 8 April 2019 and was incorporated into the unit to run a cross-functional Sexual Assault Response Team (SART) and to organise programmes that combat gender-based violence and other forms of gender injustice.

“We have been able to offer our services with minimal disruption throughout the year,” says Geraldine Lengau, a Bloemfontein Campus-based GEADO officer.

“Most exciting for us is that we have taken the lockdown as an opportunity to expand the scope of ways in which we engage with students and communities,” notes Chelepe Mocwana, a GEADO officer on the South Campus. “GEADO has offered a number of online webinars and seminars, and the university has made telephonic services available that support, for example, the mental health of survivors of sexual violence.”

“On the Qwaqwa Campus, where we still have some problems with consistent access to data networks, we were pleased to see that our webinars have been well-subscribed to by students and staff members,” reports Siya Magayana, who is the GEADO officer on this campus.

“Each such step makes a big difference by saying that the
lives of survivors matter and by underscoring that
gender-based violence will not be tolerated at the UFS.”
—Prof Colin Chasi, Director of the UICSJ.

Since 1991, activists around the world have annually coordinated activities around the 16 Days of Activism against Gender-Based Violence. The 16 days of activism begin on 25 November, the International Day for the Elimination of Violence against Women, and run until 10 December, which is International Human Rights Day. The start and end dates signify that the fight to eliminate violence against women advances human rights for all.

Activities to mark the 16 Days of Activism against Gender-Based Violence will be advertised on various UFS communication platforms.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept